Rapid subcutaneous progression after immunotherapy in pretreated patients with metastatic carcinoma: two case reports.

ABSTRACT: There is heterogeneity in cancer patients' responses to immune checkpoint inhibitors (ICIs), including hyperprogression, which is very rapid tumor progression following immunotherapy, and pseudoprogression, which is an initial increase followed by a decrease in tumor burden or in the number of tumor lesions. This heterogeneity complicates clinical decisions because either premature withdrawal of the treatment or prolonged ineffective treatment harms patients. We presented two patients treated with ICIs with heterogeneous responses. One patient had Merkel cell carcinoma in the right thigh, and the other had nasopharyngeal squamous carcinoma. The first patient was treated with sintilimab and the second with sintilimab combined with abraxane. In the first patient, subcutaneous lesions grew su

SUBMITTER: Da Y 

PROVIDER: S-EPMC9087252 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature